The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →A Swiss team reported a microfluidic chip that could analyse 1,024 blood samples while measuring four protein biomarkers in parallel. The 2013 account described a 5-nanolitre blood input, fluorescence-based detection, more than 4,000 biomarker assays in a run and an estimated reagent cost of US$0.10 per chip. Those are historical performance figures from a laboratory platform—not evidence that a consumer cancer test or clinically approved product exists.
What “1,024 samples on one chip” means
The headline count refers to the chip’s sample capacity: 1,024 individual blood samples could be placed on a single microfluidic device for analysis. The Royal Society of Chemistry’s Lab on a Chip blog, in coverage published on 19 December 2013, rounded that description to “over 1,000 blood samples.” Keeping both numbers matters. “1,024” is the specific figure used in the title and associated platform description; “over 1,000” is the wording used in the contemporary news report.
As an Amazon Associate I earn from qualifying purchases.
Jose L. Garcia-Cordero and Sebastian J. Maerkl, at the Swiss Federal Institute of Technology in Lausanne, described the device in the 2014 Lab on a Chip advance article, “A 1024-sample serum analyzer chip for cancer diagnostics” (DOI 10.1039/C3LC51153G). The work was a high-density serum-analysis platform. It was not a diagnosis delivered to patients, and the title’s reference to cancer diagnostics describes the intended analytical application rather than a validated cancer-screening service.
How the chip performed the measurements
1. Microspotting placed many samples
The platform used microspotting to deposit tiny portions of blood onto defined locations on the chip. Instead of moving each specimen through a separate full-size laboratory tube or well, the spotting step arranged a large sample set in a compact format. The reported input was 5 nanolitres of human blood for a measurement.
#1 Best Overall
- ◓DESIGN: Cross-junction microfluidic chip designed for precise droplet generation and microsphere formation in laboratory settings
- ◓There are design drawings in the picture, please check and compare carefully before buying to ensure that the chip design meets your needs
- ◓APPLICATION: Perfect for fluid dynamics research, particle synthesis, and microfluidic experiments in research laboratories
- ◓CONFIGURATION: Features integrated channels in a cross-pattern layout for controlled fluid mixing and droplet formation
- ◓DIMENSIONS: Compact size suitable for standard microscope stages, with microchannels precisely engineered for consistent results
That volume is exceptionally small compared with the amount cited for a conventional enzyme-linked immunosorbent assay (ELISA). The RSC account used 50 microlitres as a typical ELISA sample volume. Since 50 microlitres equals 50,000 nanolitres, 5 nanolitres is 10,000 times less liquid by simple unit conversion. That is a volume comparison only; it does not mean the chip was 10,000 times more sensitive, faster or clinically superior to ELISA.
2. A microfluidic circuit ran four immunoassays in parallel
After spotting, a microfluidic circuit routed assay reagents across the sample locations. The device was designed to run four parallel immunoassays, allowing four protein biomarkers to be measured from the same broad sample set. In an immunoassay, binding between an antibody and its target protein is converted into a measurable signal. Here, the signal was fluorescence.
Running four biomarker measurements across 1,024 samples creates a large assay matrix. Multiplying those two dimensions gives 4,096 individual sample-biomarker combinations, which explains why the report described the platform as capable of performing more than 4,000 disease-biomarker assays in one run. The “more than 4,000” wording is the reported run-level claim; it should not be read as a list of 4,000 different biomarkers.
Recommended Free Tools
Rank #2
- VERSATILE STANDARD CHIP: Dual-width channels (50µm & 100µm) in a simple layout — perfect for proof-of-concept experiments and protocol development.
- ENTRY-LEVEL & AFFORDABLE: The most cost-effective way to start microfluidics — ideal for students, teaching labs and teams testing new protocols.
- STARTER KIT INCLUDED: Comes complete with PTFE tubing and a syringe, giving students and researchers everything needed to begin microfluidics experiments right out of the box.
- QUALITY PDMS/GLASS BUILD: RTV615 PDMS plasma-bonded to borosilicate glass; optical clarity for fluorescence and brightfield imaging.
- PRACTICAL FORM FACTOR: Compact 45x20mm size with multiple inlet/outlet ports for flexible fluid routing.
3. Fluorescence quantified the proteins
The chip used fluorescence to quantify biomarker levels. Fluorescent intensity is an optical readout: the measured signal is related to the amount of target captured by the assay chemistry. The report did not establish that the platform used an electronic detector in a finished point-of-care instrument. Maerkl expressed the hope that an electronic readout could eventually support smaller, cheaper point-of-care devices. That was a future direction, not a market-launch announcement.
Reported specifications at a glance
| Measure | Figure reported for the chip | How to interpret it |
|---|---|---|
| Samples per chip | 1,024 in the title; “over 1,000” in the 19 December 2013 RSC account | A single high-density sample run, not proof that every run always reached the maximum. |
| Biomarkers measured in parallel | Four protein biomarkers | Four assay channels or readouts applied across the sample set. |
| Blood volume | 5 nL of human blood per measurement | The sample amount cited by the news coverage; preparation and other fluid requirements are not specified there. |
| Comparison sample volume | 50 μL for a typical ELISA, as cited by the RSC account | A contextual comparison, not a head-to-head clinical trial result. |
| Assays per run | More than 4,000 disease-biomarker assays | Consistent with four biomarkers measured across roughly 1,024 samples. |
| Throughput claim | Roughly 10–100 times that of then-current microfluidic platforms | Sebastian Maerkl’s estimate in the 2013 coverage, tied to the technology available at that time. |
| Reagent cost | Estimated US$0.10 per chip | A historical estimate quoted from Maerkl, not a current purchase price or total operating cost. |
| Readout | Fluorescence | An optical measurement method; the hoped-for electronic point-of-care readout was not established by the report. |
| Agreement with an established method | Results described as comparable to conventional ELISA | The wording comes from the RSC news account and does not by itself establish clinical equivalence. |
Why the architecture was important
The key advance was not simply making channels smaller. It was combining dense sample placement with parallel fluid handling. A conventional workflow may spend much of its time and consumables transferring specimens through separate wells, plates or tubes. A microfluidic layout can constrain those operations to patterned locations and very small volumes.
High sample count is especially useful when the objective is to compare many specimens under the same assay conditions. A single chip can reduce the number of separate runs needed for a study and can make it easier to apply the same four-marker panel across a large cohort. The design also aims to reduce reagent consumption: the reported 5-nanolitre sample input and US$0.10 reagent estimate point toward an emphasis on economy as well as density.
Rank #3
- 【Microfluidic Chip Packaging Film】 Full transparency, low temperature flexibility, good air permeability, thermal and chemical stability
- 【Microfluidic Chip Packaging Film】 Shore Hardness (A): 50, tensile strength (MPa): 4, tear strength (KN/m): 7
- 【Microfluidic Chip Packaging Film】 Elongation at break (%): 100, Elastic modulus: 1.7, Refractive index: 1.41, Transmittance (%): >95(2mm)
- 【Microfluidic Chip Packaging Film】 Using temperature range (C): -40 to 200, Dielectric strength (kV/mm): 12, Dielectric constant (1MHz): 2.7
- 【Microfluidic Chip Packaging Film】 1 Pcs/package
The device was also designed to interface with robotic dispensers. Michele Zagnoni, identified in the RSC coverage as a microfluidics expert at the University of Strathclyde, said that compatibility with existing robotic instrumentation could appeal to pharmaceutical companies. That observation supports a possible laboratory-automation use case: a chip that fits established liquid-handling procedures may be easier to evaluate than one requiring an entirely new workflow.
How it compares with ELISA and other microfluidic systems
Compared with ELISA
ELISA is a widely used laboratory immunoassay format. The report’s comparison focused on sample volume and result comparability: 5 nanolitres of blood for the chip versus a typical 50-microlitre ELISA sample, with results described as comparable. Those statements indicate analytical promise, but “comparable” does not answer every validation question. It does not specify sensitivity, specificity, calibration range, interference testing, reproducibility across operators or performance on diagnosed patients.
The two methods also differ in workflow. ELISA is normally performed in plates with established laboratory equipment and protocols. The chip integrates sample positioning and fluid routing into one microfluidic format. That integration may reduce liquid use, but it also makes fabrication, loading, fluidic sealing, reagent delivery and optical scanning part of the system’s performance.
Compared with earlier microfluidic platforms
Maerkl’s estimate placed the device at roughly 10 to 100 times the throughput of microfluidic platforms current in 2013. The comparison is therefore time-bounded. It is not a claim that the chip remains 10–100 times faster than every microfluidic system available today, nor does it define whether throughput means samples, assays, processing time or another laboratory metric. The account presents it as the researcher’s estimate, so readers should treat it as a historical benchmark rather than a standardized cross-platform test.
What the numbers do—and do not—tell you
- 1,024 samples describes capacity in the reported design. It does not establish that all 1,024 positions produce usable results in every run.
- Four biomarkers describes the parallel panel reported for the platform. It is not a four-marker cancer diagnosis by itself.
- More than 4,000 assays is a run-level count derived from many samples tested against four biomarkers, not 4,000 distinct disease tests.
- 5 nL is the cited blood volume per measurement. The available account does not provide a complete bill of materials for collection, pretreatment, waste or quality-control fluids.
- US$0.10 is an estimated reagent cost from the 2013 report. It is not a current price, a manufacturing cost, a clinical laboratory charge or the cost of the complete instrument.
- Fluorescence identifies the reported detection method. It does not show that a low-cost electronic reader was subsequently commercialized.
Why this was not a consumer cancer test
A laboratory platform and a clinical test have different evidentiary requirements. To become a clinical cancer test, a system would need a defined disease indication, a specified patient population, validated sample-handling procedures, analytical performance data, clinical studies, quality controls and appropriate regulatory authorization. None of those outcomes is established by the 2013 news coverage or by the bibliographic record supplied for the 2014 paper.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesThe phrase “for cancer diagnostics” should therefore be read as the application the researchers were targeting. It does not mean that the chip could tell an individual whether they had cancer, identify a cancer type, or replace imaging, pathology or a clinician’s evaluation. The four proteins measured on the reported device are biomarkers in an analytical panel; the account does not name a clinically validated decision threshold or show patient-outcome performance.
Best Value
- 【Microfluidic Chip Packaging Film】 Full transparency, low temperature flexibility, good air permeability, thermal and chemical stability
- 【Microfluidic Chip Packaging Film】 Shore Hardness (A): 50, tensile strength (MPa): 4, tear strength (KN/m): 7
- 【Microfluidic Chip Packaging Film】 Elongation at break (%): 100, Elastic modulus: 1.7, Refractive index: 1.41, Transmittance (%): >95(2mm)
- 【Microfluidic Chip Packaging Film】 Using temperature range (C): -40 to 200, Dielectric strength (kV/mm): 12, Dielectric constant (1MHz): 2.7
- 【Microfluidic Chip Packaging Film】 1 Pcs/package
Practical strengths and engineering trade-offs
Strengths suggested by the report
- Sample conservation: nanolitre-scale blood input could matter when specimens are scarce or expensive to collect.
- Parallelization: four assays across a large sample set can support broad screening of a panel in one coordinated run.
- High density: putting more than 1,000 samples on one chip can reduce the number of separate batches for a large experiment.
- Automation potential: compatibility with robotic dispensers could connect the chip to existing laboratory liquid handlers.
- Low reported reagent use: the historical US$0.10 estimate indicates the designers were targeting very low consumable consumption.
Questions an operator would still need answered
- How are blood samples prepared before microspotting, and how is evaporation controlled at nanolitre volumes?
- What controls identify a blocked channel, a failed spot or cross-contamination between neighboring samples?
- What fluorescence reader is required, and how are background signal and calibration handled?
- How consistent are results across chips, reagent lots, operators and repeated runs?
- What is the actual elapsed time for loading, incubation, washing, reading and analysis?
- Does the 1,024-sample format require specialized manufacturing or a particular robotic dispenser?
The available account does not answer these operational questions. They are the kinds of details needed before a high-throughput prototype could be adopted as a routine diagnostic workflow.
Where the idea could fit in a laboratory
The most defensible near-term interpretation is as a research and high-throughput assay platform. A laboratory could use a dense chip to compare biomarker patterns across a large set of stored specimens, evaluate assay candidates or support pharmaceutical development, provided the laboratory performs its own validation. The robotic-dispenser interface is relevant here because many pharmaceutical and analytical laboratories already organize work around automated liquid handling.
A point-of-care version would require more than shrinking the same chip. It would need a robust sample-to-answer workflow, a compact and affordable reader, stable reagents, straightforward quality control and a validated interpretation method. The 2013 report records the electronic-readout idea as a hope for making such instruments smaller and cheaper; it does not document that those engineering and regulatory steps were completed.
Timeline and source context
- 19 December 2013: the Royal Society of Chemistry’s Lab on a Chip blog reported the Swiss platform’s capacity, four-marker format, 5-nanolitre sample volume, fluorescence readout, throughput estimate and reagent-cost estimate.
- 2014: Garcia-Cordero and Maerkl’s paper, “A 1024-sample serum analyzer chip for cancer diagnostics,” appeared as an advance article in Lab on a Chip, DOI 10.1039/C3LC51153G.
- What remains unestablished from these records: current commercial availability, regulatory clearance, later clinical validation, a market-ready electronic reader and present-day cost or throughput compared with newer systems.
Bottom line for readers
The 1,024-sample chip was a notable demonstration of scale in microfluidic immunoassays: many blood samples, four protein biomarkers, nanolitre sample use and thousands of assay measurements were combined on one device. Its significance lies in dense laboratory automation and resource-efficient analysis. The figures belong to a 2013–2014 technology report, so they should be understood as historical platform claims—not as specifications for a currently available consumer product or proof of a clinically validated cancer test.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
